Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says

Executive Summary

Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale

You may also be interested in...



Plan B OTC switch

Delay in decision to switch Barr's Plan B to over-the-counter status will allow FDA to evaluate the use of the emergency oral contraceptive among teenagers, Deputy Commissioner Lester Crawford indicates during House Appropriations/Agriculture Subcommittee hearing March 11. FDA extended Plan B's user fee date by 90 days to May 21 (1"The Pink Sheet" March 15, 2004, p. 20)...

Plan B OTC switch

Delay in decision to switch Barr's Plan B to over-the-counter status will allow FDA to evaluate the use of the emergency oral contraceptive among teenagers, Deputy Commissioner Lester Crawford indicates during House Appropriations/Agriculture Subcommittee hearing March 11. FDA extended Plan B's user fee date by 90 days to May 21 (1"The Pink Sheet" March 15, 2004, p. 20)...

Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data

Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel